Compare BridgeBio Pharma Inc (BBIO) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Plby Group Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Plby Group Inc trades at $1.33 (market cap $139.87M). The key difference: BridgeBio Pharma Inc is far larger — about 118.8× Plby Group Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | PLBY | |
|---|---|---|
Market Cap | $16.61B | $139.87M |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $2.71 |
52-Week Low | $47.29 | $1.11 |
Enterprise Value | $18.16B | $287.68M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
